Back to Sunitinib

Sunitinib

Showing 1 study arm with grade ≥3 adverse event data (treatment-related and RT-related). Click a column header to sort.

Note on patient counts: some articles reported only percentages rather than absolute numbers. Where this occurred, the number of patients — including those with grade ≥3 adverse events — was derived by applying the reported percentage to the total arm size, which may produce a non-integer value. These figures have been rounded to the nearest integer for display.

1st Author⇅	Year⇅	Study Type⇅	Title⇅	DOI⇅	clinical trial number⇅	number of patients⇅	median/mean age⇅	tumor type⇅	treatment setting⇅	drug group⇅	drug name⇅	if other, please specify⇅	number of SBRT courses⇅	intracranial / extracranial⇅	treated site⇅	If other treated site, please specify⇅	median/mean total RT dose [Gy]⇅	minimum total RT dose [Gy]⇅	maximum total RT dose [Gy]⇅	median/mean number of fractions⇅	minimum number of fractions⇅	maximum number of fractions⇅	median/mean dose per fraction [Gy]⇅	minimum dose per fraction [Gy]⇅	maximum dose per fraction [Gy]⇅	toxicity type⇅	patients with acute G>=3 toxicity⇅	patients with late G>=3 toxicity⇅	patients with G>=3 toxicity, timing unspecified⇅	G>=3 AEs⇅	patients with G>=3 AEs⇅	details on G>=3 toxicity⇅	details on G>=3 toxicity in RT field⇅
Kao et al.	2014	Prospective	Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial	10.1007/s11523-013-0280-y	Missing	46	64	Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Melanoma, Kidney cancer, other, HCC, pancreas	oligometastatic	Multi-target TKI	Sunitinib	—	85	extra-cranial	lung, liver, bone, LN unspecified, other	visceral (adrenal, thyroid, inferior vena cava, chest wall)	50	40	50	10	10	10	5	4	5	Treatment-rel.	—	—	15	any G3: 21 AEs, any G4: 3 AEs, any G5: 2 AEs	any G3: unknown pts, any G4: unknown pts, any G5: 2 pts	any G3: anemia, neutropenia, LFT abnormalities, thrombocytopenia, nausea/vomiting, bleeding, metabolic abnormalities, increased creatinine, any G4: anemia, thrombocytopenia, any G5: bleeding (of whom 1 pt due to reirradiation given prior to study treatment, not due to SBRT given in study)	/